Eyes on Expansion
A round-up of the latest expansion plans and new facilities as building fever grips the industry
Stephanie Sutton |
Summer is the season for sun, sea, sand… And a raft of new and expanded manufacturing plants. May and June have seen something of an expansion craze with companies big and small announcing new investments – and biologics seem to be a key focus.
AstraZeneca says that biotech products now make up half of its pipeline and recently announced that it was investing $285-million in a new plant for filling and packaging protein therapeutics in Södertälje, Sweden. By the end of 2018, the facility is expected to supply biologic medicines for AstraZeneca and MedImmune’s clinical trial programmes, moving on to commercial products once fully operational in 2019. The company also bolstered its biologics manufacturing capabilities in the US at the end of 2014 with a $200-million project to expand its Frederick, Maryland site, which currently produces pediatric medications and investigational biologic products. But small molecules have not been entirely forgotten; in June, AstraZeneca announced that was partnering with two Algerian companies to create a new plant for small molecules in Algeria.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.